# Junta clínica — PT-pseudo_47d8b39fd07f (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_47d8b39fd07f",
  "pid": "PT-pseudo_47d8b39fd07f",
  "task": 1,
  "psa": 21.0,
  "age": 60,
  "months": 1,
  "pirads": "3",
  "psad": 0.19,
  "psav": 5.99,
  "psap": 23.5,
  "vol": 112.15,
  "dre": "Normal",
  "bx": "Negative",
  "cspca": 0.4009605,
  "medhx": "Hypertension, COPD",
  "meds": "amlodipine, valsartan, lisinopril, metoprolol, tiotropium, salbutamol PRN",
  "notes": "PSA 21 ng/mL. PI-RADS 3. PSAD 0.19. Prostate volume 112 mL. csPCa 0.40.",
  "pmhx": [
    "Hypertension",
    "COPD"
  ],
  "allergies": [],
  "vitals": {
    "weight": "78 kg",
    "height": "186 cm",
    "bmi": "22.5",
    "bp": "140/82 mmHg",
    "hr": "74 bpm",
    "smoking": "Non-smoker",
    "last_dental": "3 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "22 Jan 2025",
  "enc_ref": "Dr. R. van den Berg (GP)",
  "enc_type": "Re-evaluation - prior negative biopsy",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Rising PSA trajectory combined with intermediate mpMRI findings warrants specialist review following a previously Negative biopsy."
    },
    {
      "s": "History",
      "t": "The patient, a 60-year-old retired baker, initially presented for evaluation of PSA elevation in early 2022, with values climbing to 23.5 ng/mL before stabilizing at 21.0 ng/mL. He reports moderate lower urinary tract symptoms, chiefly nocturia and a weak stream, yielding an IPSS score of 17. A Non-smoker, his past medical history encompasses well-controlled hypertension and mild COPD, currently managed with amlodipine, valsartan, lisinopril, metoprolol, tiotropium, and salbutamol PRN. He maintains an active lifestyle, cycling to work five days weekly, and drinks roughly seven units of alcohol each week. Married, he resides in a multi-generational household with his wife and adult son, a setup he describes as highly supportive. Beyond urinary complaints, he notes stable right knee osteoarthritis that required six physiotherapy sessions last year, alongside occasional mild insomnia. He explicitly denies bone pain, haematuria, or unexplained weight loss. He has previously declined research study participation and wishes to maintain that position."
    },
    {
      "s": "Physical examination",
      "t": "DRE: Normal exam. Prostate texture is symmetrically enlarged, smooth, and firm, lacking discrete nodules or asymmetry. General assessment remains unremarkable, recording blood pressure at 140/82 mmHg and heart rate at 74 bpm, with no peripheral lymphadenopathy or abdominal masses detected."
    }
  ],
  "occupation": "retired baker",
  "marital": "Married",
  "living": "Lives with adult child (multi-generational household)",
  "next_of_kin": "Adult son (primary contact)",
  "recent_other": [
    "GP practice nurse — flu vaccination",
    "Physiotherapy — lower back, six sessions",
    "Radiology — chest X-ray (routine)"
  ],
  "alcohol": "7 units / week",
  "exercise": "Cycling 5x/week (commuter)",
  "ipss": "IPSS score: 17/35 (moderate LUTS)",
  "admin": "Patient declined research participation previously; respect for AS-related trials.",
  "mri_hospital": "LUMC (Leiden)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_47d8b39fd07f
Task: 1

Encounter: Urology - outpatient on 22 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 60-year-old male
  - PSA: 21.0 ng/mL
  - mpMRI — PI-RADS score: 3 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.19 ng/mL²
  - PSA velocity: 5.99 ng/mL/yr
  - Prior PSA: 23.5 ng/mL
  - Prostate volume: 112.15 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.4009605 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, COPD
  - Problem list / PMHx: Hypertension, COPD
  - Current medication: amlodipine, valsartan, lisinopril, metoprolol, tiotropium, salbutamol PRN
  - Allergies: NKA
  - Additional notes: PSA 21 ng/mL. PI-RADS 3. PSAD 0.19. Prostate volume 112 mL. csPCa 0.40.

Vitals: weight 78 kg, height 186 cm, BMI 22.5, BP 140/82 mmHg, HR 74 bpm. Smoking: Non-smoker.

Chief complaint: Rising PSA trajectory combined with intermediate mpMRI findings warrants specialist review following a previously Negative biopsy.

History: The patient, a 60-year-old retired baker, initially presented for evaluation of PSA elevation in early 2022, with values climbing to 23.5 ng/mL before stabilizing at 21.0 ng/mL. He reports moderate lower urinary tract symptoms, chiefly nocturia and a weak stream, yielding an IPSS score of 17. A Non-smoker, his past medical history encompasses well-controlled hypertension and mild COPD, currently managed with amlodipine, valsartan, lisinopril, metoprolol, tiotropium, and salbutamol PRN. He maintains an active lifestyle, cycling to work five days weekly, and drinks roughly seven units of alcohol each week. Married, he resides in a multi-generational household with his wife and adult son, a setup he describes as highly supportive. Beyond urinary complaints, he notes stable right knee osteoarthritis that required six physiotherapy sessions last year, alongside occasional mild insomnia. He explicitly denies bone pain, haematuria, or unexplained weight loss. He has previously declined research study participation and wishes to maintain that position.

Physical examination: DRE: Normal exam. Prostate texture is symmetrically enlarged, smooth, and firm, lacking discrete nodules or asymmetry. General assessment remains unremarkable, recording blood pressure at 140/82 mmHg and heart rate at 74 bpm, with no peripheral lymphadenopathy or abdominal masses detected.

Patient info: retired baker; Married; Lives with adult child (multi-generational household).
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 7 units / week; exercise Cycling 5x/week (commuter); IPSS score: 17/35 (moderate LUTS).

Recent other appointments: GP practice nurse — flu vaccination; Physiotherapy — lower back, six sessions; Radiology — chest X-ray (routine).
Admin: Patient declined research participation previously; respect for AS-related trials.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.31
  uncertainty  +/- 0.16 epistemic (95% band 0.00-0.63); among patients I cannot tell apart the outcome was 0.89 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior negative biopsy. My criterion answers DEFER.

The criterion: repeat, targeted, when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for an unchanged PI-RADS 3 or lower picture. In the labelled series this criterion matched the reading urologist in 16 of 18 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 18 labelled men in this same situation (Negative prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.00 — IDENTICAL PANEL: this is the same case, already in the labelled series: PI-RADS 3, PSA 21.0, PSAD 0.19, age 60, DRE Normal -> DEFER (clear). He wrote: "No need for biopsy while higher PSA earlier with PIRADS 3 (unchanged?)"
  2. distance 1.67: PI-RADS 3, PSA 7.4, PSAD 0.16, age 61, DRE Normal -> DEFER (uncertain). He wrote: "At what PSA level the prior biopsy was taken? If PIRADS 3 is new and PSA is significantly rising since last biopsy I would consider repeat biopsy an option"
  3. distance 2.54: PI-RADS 4, PSA 9.2, PSAD 0.16, age 54, DRE Normal -> BIOPSY (uncertain). He wrote: "Again earlier MRI report is missing, If new PRADS 4 lesion biopsy is needed as PSA is rising as well"

PRECEDENT: DEFER. The nearest precedent is this very patient, so the library returns what the reading urologist actually did with him. That is a record, not a judgement; out of sample this expert is worth only what the distance is worth.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. This patient is in the labelled series, so what follows is the reading urologist's own trace for him, not a prediction.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: fh=noted, cspca=noted, psad=noted, pirads=important, vol=decisive, bx=decisive, dre=noted, psa=important, comorbidity=noted, age=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines link the decision to biopsy to the PI-RADS score and PSA density. The guideline states that a PI-RADS threshold of $\ge 3$ is used to trigger biopsy, noting that this approach may miss some ISUP GG $\ge 2$ cancers in biopsy-naïve patients.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of no biopsy is not decisive because the guideline suggests a PI-RADS $\ge 3$ threshold is used to trigger biopsy, and this patient has a PI-RADS 3 finding. Expert 4's criterion, which suggests deferral for unchanged PI-RADS 3, is not settled because the guideline notes that repeat biopsy should be considered depending on risk factors like PSA density.

WHAT WE STILL NEED
The guideline requires knowing the PSA density to apply the risk-adapted matrix table. The panel shows the PSA density is $0.19 \text{ ng/mL}^2$, which falls into the $0.15-0.20 \text{ ng/mL}^2$ category. The guideline requires knowing the grade of the prior biopsy to determine the appropriate pathway.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on whether the PI-RADS 3 finding, combined with the PSA density and prior biopsy status, warrants a biopsy according to the EAU guidelines.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone of the PI-RADS 3 finding?
  psa_trend (get_psa_trend) -> What is the trend of the serial PSA values?
  previous_notes (get_previous_notes) -> What was the management context regarding the prior biopsy, including the grade, number, and dates of biopsy sessions, and whether surveillance is planned?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the grade (Gleason or ISUP) of the prior biopsy?

On the plan itself: Dropped 1 question(s) that asked for a value already printed on the panel: "Given the PI-RADS 3 finding and the PSA density of 0.19 ng/mL², does the EAU guideline's risk-adapted matrix table suggest a biopsy is required?".

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: mpMRI Prostate | LUMC | 15 Jan 2025
What is the lesion size and zone of the PI-RADS 3 finding?
The report states: "T2 sequences show a 12 mm focus in the right mid-gland peripheral zone, showing intermediate signal with subtly indistinct borders."

psa_trend
What is the trend of the serial PSA values?
The trend shows values: {"date": "Mar 2022", "val": 2.5}, {"date": "Feb 2023", "val": 6.9}, {"date": "Feb 2024", "val": 19.3}, {"date": "Jan 2025", "val": 21.0}.

previous_notes
What was the management context regarding the prior biopsy, including the grade, number, and dates of biopsy sessions, and whether surveillance is planned?
The notes state: "27 May 2024 - Dr. R. van den Berg (GP): Repeat testing shows PSA elevation to 23.5 ng/mL. LUMC imaging identified a PI-RADS 3 lesion, while the earlier systematic biopsy yielded Negative results. Urology re-evaluation was scheduled to review the imaging and laboratory data."

WHAT I DID NOT OPEN
family-history anamnesis, because the information was not required to answer the open questions or the specific questions attached to the documents opened.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS 3 finding, as per EAU guidelines, suggests a threshold for consideration.
PSA density of $0.19 \text{ ng/mL}^2$ falls into the category that requires further risk-adapted assessment.

Findings that argue AGAINST sampling this patient now:
Prior biopsy was Negative.
The PI-RADS score is 3, which Expert-Cohort suggests warrants deferral for unchanged findings.

WHERE THIS LEANS
The documents confirm the PI-RADS 3 finding and the prior negative biopsy status, which aligns with the Expert-Cohort's suggestion to defer.
LEAN: defer

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: INDETERMINATE (uncertain). Last value 21.00 ng/mL over 4 points spanning 34 months; velocity +7.18 ng/mL per year; doubling time about 11 months.
PROJECTION at 6 months: 24.0 ng/mL, conformal 95% band 6.9-83.7.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.44
  uncertainty  +/- 0.15 epistemic (95% band 0.15-0.74), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 59% of the time over the 29 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.31  ('supports' tier)
  EXPERT-FUSION      DEFER, p(biopsy)=0.44  ('discuss' tier, fusion_nolab)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.02  (identical panel in the series)
  EXPERT-COHORT      DEFER  (rule pirads_le_3)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: identical precedent in the labelled series — carried by EXPERT-LIBRARY.
PANEL ANSWER: NO BIOPSY. The labelled series contains this exact panel; the library returns the reading urologist's own decision for it. Out of sample this rung never fires.

Confidence the trace model expects here: clear. Weights it expects: fh=noted, cspca=noted, psad=noted, pirads=important, vol=decisive, bx=decisive, dre=noted, psa=important, comorbidity=noted, age=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened—radiology\_report, psa\_trend, and previous\_notes—did not answer the moderator's question regarding the grade of the prior biopsy (Q1). The registrar reported that the previous biopsy yielded "Negative results," but the specific grade (Gleason or ISUP) was not retrieved.

ALIGNMENT WITH THE PANEL
The retrieved evidence aligns with the PANEL-PROTOCOL's answer of NO BIOPSY, as the protocol states the rule fired due to an "identical precedent in the labelled series" carried by EXPERT-LIBRARY.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the grade (Gleason or ISUP) of the prior biopsy? This question remains unanswered by the retrieved documents.

WHAT CARRIES WEIGHT, AND WHY
The PSA density ($0.19 \text{ ng/mL}^2$) and the prior negative biopsy status are relevant because the EAU guideline requires knowing the PSA density for risk-adapted assessment, and the prior biopsy status is a key variable in the cohort criterion.

MY SUGGESTION TO THE CHAIR
Given that the required information (prior biopsy grade) was not retrieved, the panel's decision rests solely on the precedent. I suggest deferring the decision until the grade of the prior biopsy is obtained, as this is a critical variable for risk stratification.

VERDICT: not-ready | SUGGEST: defer | MISSING: previous_notes

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

The panel protocol concluded with a decision of no biopsy based on an identical precedent in the labelled series. While the cohort criterion suggested deferral due to the PI-RADS 3 finding and prior negative biopsy, the verifier noted that the critical information regarding the prior biopsy grade was missing. Therefore, the decision remains uncertain until the grade of the prior biopsy is obtained to properly risk-stratify the patient.

What carried weight: cspca=noted, psad=noted, pirads=important, vol=decisive, bx=decisive, psa=important, comorbidity=noted, age=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
